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Although the prevalence of Helicobacter pylori infection in 
Indonesia is lower than that in other countries, H. pylori is 
still an essential pathogen associated with severe gastric 
mucosal damage and dyspeptic symptoms. Invasive diag-
nostic methods are not ideal due to the lack of endoscopic 
centers and high costs without full coverage by social insur-
ance. Among the noninvasive methods, the urea breath test 
is widely available in Indonesia and has been suggested as 
the primary option to ensure the successful eradication of H. 
pylori. There has been no local validation for the urea breath 
test utilizing 13C or 14C. The stool antigen test is inexpensive 
and suitable for use in active infections before and after 
eradication; however, customs and habits are obstacles to 
delivering fresh stool on time. Only polyclonal antibodies 
and qualitative stool antigen test kits with low sensitivity are 
available. Serology is a widely validated method and has 
good accuracy, but it cannot distinguish between active and 
inactive infections. According to our observations, serology is 
the main choice of experts and patients, as it is simple, inex-
pensive and widely known. The urine test is an alternative for 
reducing costs and endoscopic workload, with high accuracy 
but low sensitivity. Further studies are necessary to prove 
the validity of the urine test to be used throughout Indonesia, 
especially in areas with a low prevalence of H. pylori infec-
tion. In conclusion, the validated urea breath test and the 
stool antigen test are considered noninvasive practical ap-
proaches for the detection of H. pylori infection in Indonesia, 
with serological and urine tests as alternatives. (Gut Liver, 
Published online November 8, 2019)
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INTRODUCTION
Some invasive diagnostic methods, such as the rapid urease 
test, histopathology and culture, have been developed to de-
tect Helicobacter pylori, a Gram-negative bacterium that is the 
primary cause of chronic gastritis, gastric atrophy and gastric 
cancer.1 Invasive tests are accurate and commonly used in daily 
practice. However, inexpensive, simple, convenient and user-
friendly indirect tests, such as the urea breath test (UBT), the 
stool antigen test (SAT) and serology, have been introduced to 
diagnose H. pylori infection.2 
Indonesia consists of 18,108 islands inhabited by 267,842,292 
people, the 4th largest population in the world. The prevalence 
of H. pylori infection in Indonesia is 22.1%,3 which is relatively 
low compared with neighboring countries such as Malaysia, 
Thailand and the Philippines, with prevalence of 24.3% to 49%, 
54.1% to 76.1% and 60%, respectively.4-6 Water source, age, and 
religion are risk factors for H. pylori infection among several 
ethnic groups in Indonesia.3 The m2 type of vacA middle region, 
East Asian type cagA with 6-bp deletion and EPIYT motif, dupA 
negative, and double-positive jhp0562/β-(1,3)galT are the pre-
dominant virulence factors that may associated with lower in-
cidence of gastric cancer.7 We found that the complete integrat-
ing conjugative elements TFSS 4b type were less predominant 
and tended to have higher severity in the gastric mucosa.8 In 
Indonesia, the prevalence of metronidazole- and levofloxacin-
resistant strains is high, but the prevalence of amoxicillin- and 
tetracycline-resistant strains is low. We suggest that in some 
regions of Indonesia, clarithromycin- or metronidazole-based 
triple therapy should be carefully considered for eradicating H. 
pylori.9 To counter high rates of metronidazole and clarithromy-
cin resistance, furazolidone-, rifabutin- and sitafloxacin-based 
therapies might become alternative regimens, while sitafloxacin 
should be considered for eradication of levofloxacin-resistant 
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Dyspepsia is the 5th-highest prevalent diseases among inpa-
tients and the 6th-highest among outpatients in Indonesia.11 In 
addition, a high prevalence of gastroesophageal reflux disease 
was found in an area of Indonesia with a low prevalence of H. 
pylori infection, with high rates of several risk factors, includ-
ing smoking, a history of proton pump inhibitor (PPI) use and 
higher economic group.12 However, the use of gastrointestinal 
(GI) endoscopy in Indonesia is still limited. In 2013, there were 
only 515 accredited GI endoscopists among 252 million people, 
for a ratio of 1:489,320.11,13 In comparison, the ratio of endosco-
pists to the total population is 1:37,037 in the United States and 
1:49,000 in England.11 The number of hospitals in Indonesia 
that are able to provide GI endoscopy services is limited to only 
313 hospitals in 33 provinces, most of them on Java Island.11 
Thus, the use of invasive diagnosis in Indonesia has many ob-
stacles due to the limited availability of endoscopy. In this re-
view, we summarize the current status of noninvasive diagnosis 
of H. pylori infection in Indonesia and make some recommen-
dations (Table 1).14-16
UREA BREATH TEST 
During infection, H. pylori has the ability to produce highly 
active urease, an enzyme that converts urea to ammonium and 
labelled CO2 in the stomach.
14,15 In the UBT, isotope-labelled 
urea is consumed by the patient, and then H. pylori breaks 
down urease enzyme products in the stomach.16 The labelled 
CO2 diffuses into epithelial cells, is absorbed into the blood and 
is excreted through the lungs.14 The labelled CO2 is detected in 
the exhaled breath after 10 minutes and serves as an indicator 
of the presence of H. pylori.16,17 With a sensitivity and specific-
ity of more than 90%, the UBT is the best noninvasive method, 
although it is less reliable in patients with a history of gastric 
resection or use of PPIs.14
In the UBT test, urea is labelled by the stable heavy isotope 
13C or the radioactive isotope 14C.18 13C-UBT is noninvasive and 
accurate, but it is relatively expensive due to the requirement 
for mass spectrometric analysis, which is only available in 
large cities. 13C-UBT is safer in pediatric patients and pregnant 
women because it does not use a radioactive isotope. Among 34 
provinces of Indonesia, 13C-UBT is available in only 10 centers 
in four main cities: three centers in Jakarta and two centers in 
Table 1. Helicobacter pylori Noninvasive Tests and the Current Situation in Indonesia
Diagnostic 
test
Sensitivity14-16 Specificity14-16 Advantage Disadvantage Situation in Indonesia
UBT 95% 95% High accuracy
Detect current infection
Less reliable in patients with  
history of gastric resection or 
PPI consumption
13C-UBT and 14C-UBT remain 
restricted to 4 and 6 cities, 
respectively
Expensive and uncovered by 
social insurance
Ongoing validation 
SAT 94% 92% Inexpensive and not age  
dependent
Novel monoclonal antibodies 
are not influenced by PPI
ICA-based, does not require 
special equipment or experts
Inconsistent accuracy based  
on antigens 
Accuracy influenced by  
incubation time and stool 
condition
Most centers use ICA-based 
tests, but with low sensitivity
Collecting stools is more difficult 
than collecting blood samples
Serology 90% 80% Saves costs and reduces  
endoscopic workload
Less accurate in children
Wide range of cutoff values 
Cannot distinguish between  
current and past infections
Lower accuracy than ICA-based 
tests
Most widely used
Validated for some kits
Urine test 93% 92% Easy sampling method without 
special skills and tools
Sampling cheaper than serum 
sampling
False negative results with  
low concentrations of IgG 
Lower accuracy 
Requires more time to interpret
Lack of availability 
UBT, urea breath test; PPI, proton pump inhibitor; SAT, stool antigen test; ICA, immunochromatographic assay; IgG, immunoglobulin G.
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Surabaya on Java Island, three centers in Medan on Sumatera 
Island, and two centers in Makassar on Sulawesi Island. In ad-
dition, this test is not covered by Indonesian social insurance. 
With a cost of Indonesian Rupiah (IDR) 1,200,000 (U.S. Dollar 
[USD] 85 estimated in July 2019), this method is relatively ex-
pensive and may not become a common method for detection 
of H. pylori. Recently, 13C-UBT has been performed using a sim-
pler infrared spectrophotometer, which is more compact, cost 
effective and easy procedure than the mass spectrometer.12 Most 
Indonesian gastroenterologists use this method to evaluate H. 
pylori positivity after eradication beside of SAT.19,20 According 
to the Asia-Pacific consensus to improve the accuracy of the 
test, the patients should stop taking bismuth salts and antibiot-
ics for 4 weeks, PPI for 2 weeks and fast for at least 4 hours.18,21 
These preparations are not convenient for most patients, es-
pecially those with severe symptoms. Because UBiT®-IR300 
infrared spectrophotometers are not currently available, most 
Indonesian centers use a new type of infrared spectral analyzer 
(POCone FT-IR®; Otsuka Pharmaceutical Co. Ltd, Tokyo, Japan), 
which is claimed to be simpler, easy to maintain, faster and ac-
curate. We use a 75-mg tablet of 13C-urea, not a 100-mg tablet 
as previously described.22 In contrast to the recommendation for 
gurgling to avoid catalytic positive bacteria in the oral cavity 
and oropharynx,23 a film-coated tablet-based UBT (UBIT, Otsuka 
Pharmaceutical Co. Ltd.) is used without gargling. 
Validation in the United States and Europe suggested a lower 
dose of 13C-UBT (75 to 125 mg) than the original recommenda-
tion (350 mg), but not lower than 75 mg to avoid poor results.24 
The reduction a dose of 50 mg in children was found in several 
studies that have been used to diagnose H. pylori infection.22,25 
At the same dose of 13C-urea, low production of endogenous 
CO2 in younger children has a relatively high isotope ratio of 
13CO2 to 
12CO2.
25 However, in Indonesia we use a similar dose for 
adults and children. Based on the manufacturer’s instructions, 
we do not administer citric acid. A previous study suggested the 
use of citric acid to increase sensitivity and specificity,26 espe-
cially with long-term use of PPI. In addition, when citric acid 
pretreatment was not performed, the accuracy was decreased.27 
We do not have data about modification of the lateral recum-
bent position for patients with partial gastrectomy.28 Collected 
breath samples were analyzed for 13C-UBT with a cutoff value of 
2.5%, as recommended by the manufacturer. Unfortunately, this 
cutoff has not been validated for adults and children and we are 
trying to validate it. The calculated optimal cutoff points of UBT 
are important in populations that have a low prevalence of H. 
pylori infection, because they (e.g., healthy volunteers) are able 
to express higher delta over baseline (DOB) values. In contrast, 
in patients with dyspepsia in whom the prevalence of infection 
is higher than in the normal population, low DOB values must 
be considered.29
The use of 14C during pregnancy is not usually recommended 
because of radiation hazards.18 However, it has been reported 
that a lower dose of 14C-UBT can be used safely in children.25 
In Indonesia, 16 centers provide 14C-UBT: nine centers in North 
Sumatera on Sumatera Island; one center in Jakarta, two cen-
ters in West Java, two centers in East Java and one center in 
Yogyakarta on Java Island; and one center on Bali Island. All 
the centers use the HUBT-20A1 analyzer (Headway, Shenzhen, 
China) with a 14C-urea capsule containing 27.8 kBq of radiation. 
Following the manufacturer’s instructions, we use a cutoff value 
of 50% to detect H. pylori infection. Currently, we are validat-
ing 14C-UBT in difference rate of H. pylori infection. In areas 
such as Indonesia with a lack of access to endoscopy, the use of 
UBT could minimize the number of endoscopies and the associ-
ated expenses to the healthcare system and patients’ discomfort. 
Modifications of the 14C-urea dose and breath-collection times 
may solve the problem of the use of 14C-UBT in pregnant wom-
en and children, although the use of 14C-UBT in these patients is 
still not accepted in Indonesia. 
STOOL ANTIGEN TEST
The SAT is noninvasive and inexpensive, and its diagnostic 
accuracy is not dependent on age.30 Enzyme immunoassay (EIA) 
based on polyclonal antibodies was the first method of SAT and 
had high accuracy.31 However, most of the results were incon-
sistent, and a monoclonal antibody-based approach was devel-
oped, which has been shown to reduce false positive findings 
and increase specificity.32 The pretreatment monoclonal antigen 
technique was superior to polyclonal technique, with a specific-
ity of 97% versus 94%, sensitivity of 96% versus 90%, positive 
predictive value of 96% versus 91% and negative predictive 
value of 97% versus 85%.33 Four to eight weeks of antisecre-
tory therapy also showed that the monoclonal antigen was bet-
ter than the polyclonal antigen.33,34 In Indonesia, the SAT does 
not require expensive special equipment and chemicals and is 
cheaper than UBT. It is widely used throughout the country with 
a cost of IDR 300,000 (USD 20 estimated July 2019). In addi-
tion, the SAT does not require fasting and, with novel monoclo-
nal antibodies, does not require discontinuation of PPIs.35
EIA and immunochromatographic assay (ICA) are both meth-
ods of SAT. EIA has better accuracy than ICA, even though the 
latter uses monoclonal antibodies.36,37 EIA-based assays, such as 
the commercial kit Premier Platinum HpSA (Meridian Diagnos-
tic, Cincinnati, OH, USA) may be applicable in Indonesia. After 
mixing the stool sample with 200 µL of sample diluents, enzyme 
conjugate is added to the microplate. The mix was incubated for 
1 hour at room temperature and washed five times. The results 
are read by spectrophotometry after one drop of stop solution is 
added to end the reaction. The manufacturer’s recommendations 
indicate a positive result if absorbance (450/630) ≥0.160.38 A 
cutoff value of 0.300 is reported to provide the best diagnostic 
value, with sensitivity of 93.9%, specificity of 95.7% and accu-
racy of 94.8%; a cutoff value of 0.130 provides less sensitivity 
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(89.5%) and specificity (83.3%).39,40 However, most commercial 
laboratories in Indonesia are not interested in using this method 
because of higher costs and thus reduced potential profits.
ICA has the advantage of providing rapid diagnosis of H. py-
lori infection. ICA may be useful in developing countries with 
many remote areas, such as Indonesia. A proper accuracy of 
ICA-based SAT can be in stock in many hospitals in Indonesia, 
and the examination can be carried out in small laboratories, 
as this test does not require special equipment and experts. 
When it was applied in clinical practice for the first time, an 
acceptable sensitivity of 88% and a specificity of 94% were 
achieved.41 Most of our centers and commercial laboratories use 
a rapid SAT method with monoclonal antibodies based on re-
cently developed lateral flow ICA, such as On-Site H. pylori Ag 
Rapid Test-cassette (CTK Biotech Inc., San Diego, CA, USA).18,32 
This test is very suitable for daily practice because it has more 
practical steps.26 The manufacturer’s instructions recommend 
applying 5 to 10 mL of faces to the device that contained with 
the antibody. If H. pylori antigen is present in the stool, a reac-
tion between the antigen-antibodies and the dye will appear 
within 15 minutes as a red line in the instrument test zone. The 
negative result was determined if one red line appears in the 
control zone while the positive result was determined if two red 
lines appear in both control and test zone. The result is invalid 
if there is no red line in the control zone and the examination 
need to be repeated using a new tape. In addition, the H. pylori 
strain used in this test is different from that in Indonesia,42 Sev-
eral factors affect the results of SAT. Low amounts of antigen 
due to low colonization in the stool and low ability to react can 
produce false negative results.20 In a country such as Indonesia, 
with a low prevalence of H. pylori, the density number of H. 
pylori is also low, suggesting a high risk of low sensitivity of the 
SAT. Incubation time also is an important factor. The sensitivity 
of readings at 30 and 60 minutes can reach 76.9% and 78.6%, 
respectively, compared with 59.1% at 20 minutes.25 Formless or 
watery stools can reduce the accuracy of the test due to dilu-
tion of antigens.37 If the sample is not tested within a short time 
(less than 7 days), it must be stored at low temperature (–5° to 
–25°C). Testing of stool samples stored at –80°C for 225 days 
still provided good sensitivity and specificity.37 In Indonesia, 
collecting stools is more difficult than collecting blood samples. 
People cannot predict their defecation time well, and many may 
not feel comfortable about the delivery process.
The accuracy of the SAT for H. pylori is a concern. A valida-
tion study of Pronto Dry (Medical Instruments Corporation, 
Solothurn, Switzerland) at Cipto Mangunkusumo Hospital in 
Jakarta reported sensitivity and specificity of only 66.7% and 
78.9%, respectively, with 0.274 as the cutoff value.43 In addition, 
of 54 of 63 dyspeptic patients (85.7%) who tested positive based 
on several methods, 42 tested positive by the SAT only, which 
suggests a potential for false positive results. Therefore, the lo-
cal validation test is very important, because differences in the 
antigenicity of H. pylori strains affect the result of the SAT.32
SEROLOGY
In general, detection of specific antibodies following exposure 
to various H. pylori antigens can be a useful method in clinical 
practice because it is acceptable to patients, cheap and fast.18 
An important study reviewed 36 commercial kits used in 26,812 
patients in different populations; the sensitivity ranged from 
57% to 100% and the specificity from 31% to 100%.44 Thus, a 
validated serological test is useful for initial screening before 
the diagnosis is confirmed by histology or culture, especially 
in a country with a shortage of endoscopic centers.45 However, 
it must be noted that the test and treat strategy is not recom-
mended in areas with a low prevalence of H. pylori. Our group 
showed that an enzyme-linked immunoassay (ELISA) kit (Eiken 
Co. Ltd., Tokyo, Japan) had low sensitivity when the cutoff 
value from the manufacturer’s instructions (positive if ≥10 U/
mL, with sensitivity and specificity of 66.7% and 97.2%, respec-
tively) was used. We suggested using a cutoff value of ≥5.5 U/
mL, which increased the sensitivity to 86.7%.13 The use of sero-
logical tests for screening patients with dyspepsia can save costs 
and reduce endoscopic workload by up to 30%.33 Nevertheless, 
serological tests are not recommended for children because of 
the problem of the level of H. pylori-specific antibodies.30
Antibody preparations are closely related to the diagnostic ac-
curacy of different kits.46 Kits made in Eastern countries will be 
more accurate in detecting H. pylori strains in Eastern countries 
than kits made in Western countries. The accuracy of diagnostic 
kits from Western countries was low when applied to Japanese 
patients.47,48 In a study that compared the diagnostic accuracy 
of ELISA kits from Western and Eastern countries for detection 
of immunoglobulin G (IgG) antibodies to H. pylori in Japan, the 
accuracy of the Western kit was 86.8% and the accuracy of the 
Eastern kit was 92.3%.49 Therefore, the use of antigens of local H. 
pylori strains will affect the success of serological tests in Indo-
nesia.
Serological tests use blood samples to detect IgG antibod-
ies by ELISA. Similar to the SAT, the accuracy of EIA-based 
serological tests is better than that of ICA-based tests. A study 
that compared 29 commercial serological tests showed that nine 
of 17 EIA-based tests but only one in 12 ICA-based tests had 
an accuracy of more than 90%.2 Immunoblot assay has higher 
specificity but lower sensitivity than EIA. This method requires 
special expertise and has high costs, so it is not used in clini-
cal laboratories in Indonesia.17 ELISA is the most commonly 
used method in Indonesia. After H. pylori has been successfully 
treated, IgG antibodies to H. pylori will last for several months.50 
In addition, serological tests can result in false negatives, which 
may occur with new infections when antibody levels are not 
sufficiently elevated, because IgG antibodies appear approxi-
mately 21 days after H. pylori infection.51 We are currently 
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validating an ICA-based kit (MP Diagnostics ASSURE®; MP 
Biomedicals, Santa Ana, CA, USA) against histopathology as the 
gold standard. They proposed a recombinant current infection 
marker as an indication of current infection for covering the 
lack of serology.
URINE TEST
Several tests for detection of antibodies to H. pylori using 
urine and saliva samples have shown high sensitivity and speci-
ficity.52-54 Sampling of urine and saliva can be performed easily 
without the need for special skills or tools and is cheaper than 
sampling of serum. However, a major problem is that the con-
centrations of H. pylori antibodies in saliva and urine are lower 
than in serum.17 False negative results can occur with urine-
based ELISA. H. pylori-specific IgG has low concentration in the 
urine. A study showed that a commercial kit (RAPIRUN® stick, 
Otsuka Pharmaceutical Co., Ltd.) to detect H. pylori antibodies in 
urine was reliable for detecting H. pylori infection in Indonesia.55 
In this test, 0.3 mL of fresh urine is mixed with 0.3 mL of dilute 
solution to make an approximately 2-fold dilution, and a test 
stick is placed in the mixture. A colloidal gold-conjugated anti-
human IgG (Fc) polyclonal antibody (goat) is enclosed inside the 
test stick. H. pylori antigen is used to immobilize the test line of 
the evaluation section, and the anti-human IgG polyclonal anti-
body is used as the control line.56 If two red bands appear on the 
test line after the sample is applied for 15 minutes at 25° to 30°C, 
the result is considered positive. The result is considered nega-
tive if a red band appears on the control line only. The result is 
considered invalid due to error in the assay steps or excessively 
diluted urine if the red band is absent in the control line. The 
RAPIRUN® test validation result in Indonesia found sensitivity, 
specificity, positive predictive value, negative predictive, and 
accuracy of 83.3%, 94.7%, 71.4% 97.3%, and 93.2%, respec-
tively. In Japan and Vietnam, rapid urine tests had a sensitiv-
ity of 93.1%, a specificity 92.3% and an accuracy of 92.0%.14 
Our group also used RAPIRUN® among minor ethnic groups in 
remote areas of North Sulawesi and found identical results to 
serological test findings.57 When the urine test showed a posi-
tive result, we used a disposable gastric brush to obtain gastric 
juice and a small amount of gastric tissue for H. pylori culture. 
However, in our experience, RAPIRUN® had less accuracy in ar-
eas with low prevalence of H. pylori in Indonesia58 and required 
more time to interpret rather than manual instruction. 
CONCLUSIONS
The use of noninvasive H. pylori testing in Indonesia may 
reduce the overall endoscopic workload and the financial bur-
den on Indonesian social insurance. Validated UBT and SAT are 
considered practical approaches for the detection of H. pylori 
infection in Indonesia, with serological and urine tests as alter-
native strategies.
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